Binding of Pramipexole to Dopamine Receptors in the Human Brain
Author Information
Author(s): Ishibashi Kenji, Ishii Kenji, Oda Keiichi, Mizusawa Hidehiro, Ishiwata Kiichi
Primary Institution: Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Hypothesis
The study aimed to determine the binding sites of pramipexole in extrastriatal dopaminergic regions due to its speculated antidepressive effects.
Conclusion
Pramipexole binds significantly to D2/D3 receptors in the prefrontal cortex, amygdala, and thalamus, which may relate to its antidepressive effects.
Supporting Evidence
- Pramipexole significantly binds to D2/D3 receptors in the prefrontal cortex, amygdala, and thalamus.
- The study involved 15 healthy volunteers who underwent PET scans.
- Binding potential was calculated using both the simplified reference tissue model and the Logan plot method.
- Significant differences in receptor binding were observed after administration of pramipexole.
Takeaway
This study looked at how a drug called pramipexole attaches to certain brain receptors that might help with depression.
Methodology
Dynamic PET scanning using 11C-FLB 457 was performed on 15 healthy volunteers who received varying doses of pramipexole.
Potential Biases
Potential bias due to the small number of subjects and the use of a single reference region for analysis.
Limitations
The study had a small sample size and used low doses of pramipexole for safety.
Participant Demographics
15 healthy volunteers (7 men and 8 women; mean age 50.2 years, range 30–77).
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website